Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?

Zoe N. Memel M.D.,Jeffrey Wang B.S.,Kathleen E. Corey M.D., M.P.H., M.M.Sc. First published: 03 February 2022 https://doi.org/10.1002/cld.1172 Potential conflict of interest: KC consults for Novo Nordisk. She also consults for and received grants from Bristol-Myers Squibb. ZM own stock in Novo Nordisk.